tiprankstipranks
Advertisement
Advertisement

Vanda Pharmaceuticals doses first patient in trial of VCA-894A

Vanda Pharmaceuticals (VNDA) announced the first dose in the first-in-human clinical trial to evaluate the safety and tolerability of VCA-894A, an antisense oligonucleotide therapeutic, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1